Intellia Therapeutics Reaches Analyst Target Price
November 30, 2020 at 08:55 AM EST
In recent trading, shares of Intellia Therapeutics Inc (NTLA) have crossed above the average analyst 12-month target price of $36.94, changing hands for $39.38/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..